Pilot-scale production of a highly efficacious and stable monoglycosylated influenza split virus vaccine

In conclusion, this study provides efficacy and safety profiles of IVR-190mg for further clinical study and shows that this vaccine without a glycan shield has great potential to be safe and protective against H1N1 variants.PMID:38582606 | DOI:10.1016/j.vaccine.2023.11.038

Source: Vaccine - April 6, 2024 Category: Allergy & Immunology Authors: Chia-Ying Wu Shao-En Kao Yung-Chieh Tseng Jen-Tzu Hou Li-Yang Wu Juine-Ruey Chen Source Type: research